UniPR129

Cat. No.: HY-123607

CAS No.: 1639159-47-9

Molecular Formula: $C_{36}H_{52}N_2O_4$

Molecular Weight: 576.81

Target: Ephrin Receptor

Pathway: Protein Tyrosine Kinase/RTK

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 33.33 mg/mL (57.78 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	1.7337 mL	8.6684 mL	17.3367 mL
5 mM	0.3467 mL	1.7337 mL	3.4673 mL
10 mM	0.1734 mL	0.8668 mL	1.7337 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

UniPR129 is a potent Eph/ephrin antagonist with IC_{50}s of 0.84-3.01 μM. UniPR129 has the potential for the research of cancer disease[1][2].

IC_{50} & Target

EphA1 1.39 μM (IC_{50})	EphA2 1.12 μM (IC_{50})	EphA3 1.43 μM (IC_{50})	EphA4 1.58 μM (IC_{50})
EphA5 1.57 μM (IC_{50})	EphA6 1.53 μM (IC_{50})	EphA7 1.24 μM (IC_{50})	EphA8 0.84 μM (IC_{50})
EphB1 2.75 μM (IC_{50})	EphB2 2.96 μM (IC_{50})	EphB3 3.74 μM (IC_{50})	EphB4 2.60 μM (IC_{50})
EphB5 3.01 μM (IC_{50})			

REFERENCES

[1]. Hassan-Mohamed I, et.al. UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. Br J Pharmacol. 2014 Dec;171(23):5195-208.

[2]. Giorgio C, et al. Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction. Biochem Pharmacol. 2018;147:21-29.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA